Medication info

Dap Duo Extended Release Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hankook Hutech Pharmaceutical Co., Ltd.
Appearance
Pink, oval, biconvex, extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP)*5], 200 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202301901 · Approved 2023.06.21

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and in whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose of this medication may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since changes may lead to alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Ingredients

Manufacturer
Hankook Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in controlling blood sugar
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It is administered as an adjunct to diet and exercise therapy. Caution is particularly warranted when used in patients with existing cardiovascular disease or risk factors, especially in those whose blood glucose control is insufficient. Detailed clinical trial information related to this should be referred to in expert guidelines. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and in whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose of this medication may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since changes may lead to alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Precautions

This medication is used in the treatment of diabetes and aids in the control of blood sugar. However, it should not be administered to patients with reduced kidney function, severe infections, or dehydration. Additionally, it is advisable for women who are pregnant or nursing to avoid using this medication. Rarely, this medication may cause lactic acidosis, a dangerous condition, so consult a doctor immediately if symptoms occur. Hypoglycemia may occur when used with insulin or other diabetes medications, requiring careful monitoring of blood sugar levels. During treatment, symptoms of reduced fluid volume or low blood pressure may arise, thus regular kidney function tests should be performed, particularly in the elderly or those with compromised kidney function. There is a possibility of genital infections or urinary tract infections, and immediate treatment is necessary if related symptoms appear. This medication may lower vitamin B12 levels; thus, a vitamin B12 check is recommended during long-term use. Excessive alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. If undergoing surgery or imaging tests with contrast agents, consult healthcare professionals and temporarily discontinue this medication. The safety of this medication in children has not been established, and particular caution must be exercised in the elderly regarding decreased kidney function. In case of overdose, seek appropriate medical treatment immediately. Finally, store this medication out of reach of children and in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • fever
  • burns
  • wrist fracture
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • dental pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • fibromyalgia
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air and moisture, and keep it at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Pink, oval, biconvex, extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP)*5], 200 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.